erlotinib hydrochloride has been researched along with Uterine Cervical Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chhabra, R | 1 |
| Alves, FV; Carmo, CC; Erlich, F; Ferreira, CG; Grazziotin, R; Mamede, M; Moralez, G; Nogueira-Rodrigues, A; Small, IA; Triginelli, SA; Viegas, C | 1 |
| Camisão, C; do Carmo, CC; Erlich, F; Ferreira, CG; Fontão, K; Herchenhorn, D; Lima, R; Martins, RG; Moralez, GM; Nogueira-Rodrigues, A; Small, IA; Viegas, C | 1 |
| Lee, YC; Mannel, R; Schilder, RJ; Sill, MW | 1 |
| Diefendorf, LP; Jette, DF; Mohammed, A; Mondal, S; Moses, MA; Searleman, SA; Stevens, DA; Wilton, KM; Woodworth, CD | 1 |
| Birle, DC; Hedley, DW | 1 |
3 trial(s) available for erlotinib hydrochloride and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemoradiotherapy; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Uterine Cervical Neoplasms | 2014 |
Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Quinazolines; Radiation Oncology; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2008 |
A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
3 other study(ies) available for erlotinib hydrochloride and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer.
Topics: Cell Line, Tumor; Chromones; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; MicroRNAs; Morpholines; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Signal Transduction; SOXB1 Transcription Factors; Up-Regulation; Uterine Cervical Neoplasms | 2018 |
Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.
Topics: Apoptosis; Cell Transformation, Viral; Cervix Uteri; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Viral; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Repressor Proteins; Signal Transduction; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2011 |
Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Epidermal Growth Factor; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Quinazolines; Ribosomal Protein S6; Signal Transduction; Sirolimus; Transplantation, Heterologous; Uterine Cervical Neoplasms | 2006 |